Go Pro
→ Before Anthropic becomes impossible to ignore... (From The Oxford Club) (Ad)tc pixel Free KZIA Stock Alerts

Novogen (KZIA) News Today

Novogen logo
$12.16 -0.45 (-3.57%)
As of 09/3/2026 04:00 PM Eastern
Compare

Novogen Latest News

Novogen (NASDAQ:KZIA) Stock Price Expected to Rise, BTIG Research Analyst Says
September 3 at 1:48 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30999839
Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy
September 1 at 7:30 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-reports-preclinical-data-showing-paxalisib-reprograms-immunotherapy-resistant-msspmmr-colorectal-cancer-and-enhances-response-to-immunotherapy-302865533.html
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer
September 1 at 7:15 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-expands-paxalisib-clinical-trial-into-hrher2--breast-cancer-supported-by-preclinical-data-showing-strong-clinical-activity-and-safety-in-hr-breast-cancer-302865460.html
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering
August 31, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-limited-announces-oversubscribed-closing-of-up-to-120-million-public-offering-302865390.html
Kazia Therapeutics: Worth Speculating On Paxalisib's TNBC Data
August 31, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4941623-kazia-therapeutics-stock-worth-speculating-paxalisib-tnbc-data
Analysts Set Novogen Limited (NASDAQ:KZIA) PT at $26.33
August 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30991562
Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering
August 28, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-limited-announces-pricing-of-up-to-120-million-public-offering-302862579.html
Novogen (KZIA) Expected to Post Quarterly Earnings on Friday
August 28, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30987117
Kazia Therapeutics Limited Announces Proposed Public Offering
August 27, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-limited-announces-proposed-public-offering-302862233.html
Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer
August 27, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-reports-100-clinical-benefit-rate-in-initial-six-patients-treated-for-advanced-triple-negative-breast-cancer-302862200.html
Kazia Therapeutics ADR (KZIA) Stock Forecast & Price Target
August 9, 2026  |  investing.comhttps://www.investing.com/equities/novogen-ltd-consensus-estimates
Kazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Preclinical Data, to Prevent Metastatic Recurrence in Triple-Negative Breast Cancer
July 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/28/3334143/0/en/kazia-therapeutics-announces-the-filing-of-provisional-patent-for-novel-strategy-supported-by-preclinical-data-to-prevent-metastatic-recurrence-in-triple-negative-breast-cancer.html
Kazia Therapeutics ADR Stock Price History
June 17, 2026  |  investing.comhttps://www.investing.com/equities/novogen-ltd-historical-data
Kazia Therapeutics Appoints James Levine as Chief Financial Officer
June 2, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-appoints-james-levine-as-chief-financial-officer-302787604.html
Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
May 26, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-expands-ongoing-phase-1b-trial-of-paxalisib-in-advanced-breast-cancer-302781345.html
Kazia Therapeutics: Diverse Cancer Pipeline Still Needs A Major Catalyst
April 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4895704-kazia-therapeutics-diverse-cancer-pipeline-still-needs-a-major-catalyst
Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform
April 15, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-strengthens-scientific-leadership-with-appointment-of-dr-sudha-rao-as-chief-scientific-officer-to-lead-next-generation-oncology-platform-302742491.html
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform
April 13, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-expands-oncology-platform-with-first-in-class-setdb1-inhibitor-drug-development-platform-302740954.html
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
January 30, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-announces-compelling-preclinical-and-translational-data-for-nuclear-pd-l1-degrader-ndl2-302674710.html
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
January 27, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-reports-encouraging-preliminary-clinical-responses-in-ongoing-phase-1b-study-of-paxalisib-in-late-stage-metastatic-triple-negative-breast-cancer-302670593.html
Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End
January 8, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-to-participate-in-jp-morgan-healthcare-conference-week-clinical-and-translational-update-anticipated-before-month-end-302656513.html
Kazia Therapeutics Regains Full Nasdaq Listing Compliance
December 22, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-regains-full-nasdaq-listing-compliance-302647695.html
Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+
December 10, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-highlights-new-clinical-and-translational-findings-demonstrating-paxalisibs-ability-to-reinvigorate-anti-tumor-immunity-across-multiple-advanced-breast-cancer-populations-including-tnbc-and-her2-302637493.html
Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities
December 2, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-announces-pricing-of-50-0-million-private-placement-of-equity-securities-302630502.html
Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy
November 18, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-achieves-initial-icr-immune-complete-response-in-metastatic-tnbc-and-delivers-q4-business-update-with-breakthroughs-across-breast-cancer-immuno-oncology-and-gbm-regulatory-strategy-302618635.html
Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner
October 27, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-to-request-fda-type-c-meeting-to-discuss-overall-survival-data-in-gbm-and-potential-nda-filing-in-alignment-with-fda-initiative-project-frontrunner-302594782.html
Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program
October 7, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-announces-collaboration-and-in-licensing-agreement-for-first-in-class-pd-l1-protein-degrader-program-302576571.html
Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen
October 2, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-announces-86-reduction-in-tumor-burden-in-expanded-access-case-of-metastatic-tnbc-patient-treated-with-paxalisib-immunotherapy-regimen-302573460.html
Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG
October 1, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-supports-australian-mrff-funded-project-developing-ai-driven-sequential-therapy-strategy-for-dipgdmg-302572508.html
Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy
September 11, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-reports-complete-ex-vivo-disruption-of-large-circulating-tumor-cell-clusters-in-stage-iv-her2-positive-breast-cancer-with-paxalisib-monotherapy-302553345.html
Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market
August 1, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-announces-2-million-private-placement-at-premium-to-market-302519397.html
Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial
July 9, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-reports-early-efficacy-data-from-first-triple-negative-breast-cancer-patient-receiving-paxalisib-combination-regimen-achieving-50-reduction-in-circulating-tumor-cells-in-phase-1b-trial-302500778.html
Kazia Therapeutics Shares Jump After Data Shows Lead Asset Could Treat Breast Cancer
June 11, 2025  |  marketwatch.comhttps://www.marketwatch.com/story/kazia-therapeutics-shares-jump-after-data-shows-lead-asset-could-treat-breast-cancer-eed98f94
Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC)
June 11, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-announces-transformative-preclinical-data-demonstrating-paxalisibs-potential-to-overcome-immunotherapy-resistance-in-triple-negative-breast-cancer-tnbc-302478629.html
Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer
June 5, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-announces-first-patient-dosed-in-phase-1b-trial-of-paxalisib-in-advanced-breast-cancer-302474007.html
Kazia Therapeutics Highlights Recent Progress and Provides Business Update
May 15, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-highlights-recent-progress-and-provides-business-update-302456503.html
Vivesto AB: Vivesto signs deal with Kazia Therapeutics to acquire full Cantrixil rights
March 31, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-03/64975825-vivesto-ab-vivesto-signs-deal-with-kazia-therapeutics-to-acquire-full-cantrixil-rights-399.htm
Kazia Therapeutics sells IP, trademarks rights to Cantrixil for $1M
March 31, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/kazia-therapeutics-sells-ip-trademarks-rights-to-cantrixil-for-1m-1034533398
Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil
March 31, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-announces-sale-of-intellectual-property-and-trademarks-rights-for-cantrixil-302415424.html
Kazia Therapeutics announces research grant awarded from MJFF
February 20, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/kazia-therapeutics-announces-research-grant-awarded-from-mjff-1034386430
Maxim Group Initiates Coverage of Kazia Therapeutics Limited - Depositary Receipt () (KZIA) with Buy Recommendation
February 8, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/maxim-group-initiates-coverage-of-kazia-therapeutics-limited-depositary-receipt-kzia-with-buy-recommendation/ar-AA1yC27E
Maxim starts Kazia Therapeutics at Buy amid ‘positive’ GBM study data
February 6, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/maxim-starts-kazia-therapeutics-at-buy-amid-positive-gbm-study-data-1034322843
Kazia Therapeutics initiated with a Buy at Maxim
February 6, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/kazia-therapeutics-initiated-with-a-buy-at-maxim-1034322364
Is Kazia Therapeutics (KZIA) One of the Best ASX Stocks to Buy According to Hedge Funds?
January 31, 2025  |  msn.comhttps://www.msn.com/en-us/money/markets/why-novonix-limited-nvx-is-among-the-best-asx-stocks-to-buy-according-to-hedge-funds/ar-AA1yb95B
Kazia Therapeutics launches trial of paxalisib/immunotherapy combination
January 30, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/kazia-therapeutics-launches-trial-of-paxalisib-immunotherapy-combination-1034289109
Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer
January 30, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-announces-the-launch-of-a-groundbreaking-trial-with-paxalisib-in-combination-with-immunotherapy-in-women-with-advanced-breast-cancer-302364230.html
Why Kazia Therapeutics (KZIA) Is Among the Best Australian Stocks to Buy Now?
January 27, 2025  |  msn.comhttps://www.msn.com/en-us/money/markets/why-kazia-therapeutics-kzia-is-among-the-best-australian-stocks-to-buy-now/ar-AA1xWh4R
Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering
January 14, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-announces-closing-of-2-0-million-registered-direct-offering-302350816.html
Kazia Therapeutics to sell 1.33M ADS at $1.50 in registered direct offering
January 10, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/kazia-therapeutics-to-sell-1-33m-ads-at-1-50-in-registered-direct-offering-1034216067
Kazia Therapeutics Announces Pricing Of $2 Mln Registered Direct Offering At $1.50/ADS
January 10, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/kazia-therapeutics-announces-pricing-of-2-mln-registered-direct-offering-at-1-50-ads-1034215422

Novogen Media Mentions By Week

Novogen Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

KZIA
News Sentiment
▼
0.20

0.78
▲
Average
Healthcare
News Sentiment

Novogen News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

KZIA Articles
This Week
▼
9

1
▲
KZIA Articles
Average Week

Novogen Trends on MarketBeat

This week vs. last week
New Followers
1
Searches
4
+300%
Page Views
1,718
+39%
Get Novogen News Delivered to You Automatically

Sign up to receive the latest news and ratings for KZIA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools

Related Companies
News and Trends Tools

MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Novogen dated 9/1/2026.
From Our Partners
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
A weekly dividend fund holding Nvidia and Palantir
CrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...
Investors Alley | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
In 1984, a 10000 dollar stake in Apple could have grown to 25 million dollars for early investors who simply g...
Eagle Publishing | Sponsoredtc pixel